Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks
Summary
Product: Unauthorized injectable peptide drugs
Issue: Health products – Unauthorized product; Product safety
What to do: Consult a healthcare professional if you have used an unauthorized injectable drug on the list below and have health concerns. Do not buy or use unauthorized drugs. Only buy prescription drugs from licensed pharmacies. Read product labels to confirm a product has been authorized for sale by Health Canada.
Affected products
Unauthorized injectable peptide drugs, including:
• AOD9604
• ARA 290
• Bremelanotide
• Bronchogen
• BPC-157
• CJC-1295
• Cortagen
• DSIP
• Epitalon
• GHK, GHK-Cu
• GHRP 2
• GHRP 6
• GLP-1 (7-37)
• Gonadorelin
• Hexarelin
• HGH, HGH Fragment
• Humanine
• Ipamoreline
• Kisspeptin
• KK-23
• Livagen
• LL-37
• Melanotan 1
• Melanotan II
• NR-7
• Ovagen
• Pal-GHK
• Pinealon
• PNC-27
• Prostamax
• QS-13
• Retatrutide
• Selank
• Semax
• Sermorelin
• SS-31
• Tesamorelin
• Thymosin alpha
• Thymosin-β4 (TB4 or TB-500)
• Tirzepatide
• Vilon
• VIP
IssueHealth Canada is warning the public of seized unauthorized injectable peptide drugs from Canada Peptide. The products were being sold via the company's website. Peptide drugs affect the body's functions and are often used for bodybuilding, anti-aging, or enhancing athletic performance. Injectable peptides are regulated as prescription drugs in Canada.
Health Canada has not authorized any of the products that were seized or sold on the company's website, which means that they have not been assessed for safety, efficacy, and quality. Selling unauthorized drugs is illegal in Canada.
Prescription drugs should only be used under the care of a healthcare professional because they are used to treat specific conditions and may cause serious side effects. Unauthorized injectable drugs may:
Cause infectionallergic reactions, and other poor outcomes.
Interact with other medications an individual might be taking.
Contain high-risk ingredients, additives, or contaminants that may or may not be listed on the label.
Not have been manufactured or stored safely.
Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety, including communicating updates, if needed.
What you should do
Consult a health care professional (physician, nurse practitioner, pharmacist) if you have used an unauthorized injectable drug and have health concerns.
Follow municipal or regional guidelines on how to dispose of chemicals and other hazardous waste or return the product to your local pharmacy for proper disposal.
Only buy prescription drugs from licensed pharmacies. Be aware of the risks of buying health products online.
Do not buy or use unauthorized drugs. You can read product labels to confirm the product has been authorized for sale by Health Canada. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database.
Report any health product-related side effects or complaints to Health Canada.
Également disponible en français
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
4 days ago
- Malaysian Reserve
Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks
OTTAWA, ON, Aug. 1, 2025 /CNW/ – Summary Product: Unauthorized injectable peptide drugs Issue: Health products – Unauthorized product; Product safety What to do: Consult a healthcare professional if you have used an unauthorized injectable drug on the list below and have health concerns. Do not buy or use unauthorized drugs. Only buy prescription drugs from licensed pharmacies. Read product labels to confirm a product has been authorized for sale by Health Canada. Affected products Unauthorized injectable peptide drugs, including: • AOD9604 • ARA 290 • Bremelanotide • Bronchogen • BPC-157 • CJC-1295 • Cortagen • DSIP • Epitalon • GHK, GHK-Cu • GHRP 2 • GHRP 6 • GLP-1 (7-37) • Gonadorelin • Hexarelin • HGH, HGH Fragment • Humanine • Ipamoreline • Kisspeptin • KK-23 • Livagen • LL-37 • Melanotan 1 • Melanotan II • NR-7 • Ovagen • Pal-GHK • Pinealon • PNC-27 • Prostamax • QS-13 • Retatrutide • Selank • Semax • Sermorelin • SS-31 • Tesamorelin • Thymosin alpha • Thymosin-β4 (TB4 or TB-500) • Tirzepatide • Vilon • VIP IssueHealth Canada is warning the public of seized unauthorized injectable peptide drugs from Canada Peptide. The products were being sold via the company's website. Peptide drugs affect the body's functions and are often used for bodybuilding, anti-aging, or enhancing athletic performance. Injectable peptides are regulated as prescription drugs in Canada. Health Canada has not authorized any of the products that were seized or sold on the company's website, which means that they have not been assessed for safety, efficacy, and quality. Selling unauthorized drugs is illegal in Canada. Prescription drugs should only be used under the care of a healthcare professional because they are used to treat specific conditions and may cause serious side effects. Unauthorized injectable drugs may: Cause infectionallergic reactions, and other poor outcomes. Interact with other medications an individual might be taking. Contain high-risk ingredients, additives, or contaminants that may or may not be listed on the label. Not have been manufactured or stored safely. Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety, including communicating updates, if needed. What you should do Consult a health care professional (physician, nurse practitioner, pharmacist) if you have used an unauthorized injectable drug and have health concerns. Follow municipal or regional guidelines on how to dispose of chemicals and other hazardous waste or return the product to your local pharmacy for proper disposal. Only buy prescription drugs from licensed pharmacies. Be aware of the risks of buying health products online. Do not buy or use unauthorized drugs. You can read product labels to confirm the product has been authorized for sale by Health Canada. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database. Report any health product-related side effects or complaints to Health Canada. Également disponible en français
Malaysian Reserve
25-07-2025
- Malaysian Reserve
CIBC Recognized as a Leading Workplace for Disability Inclusion
TORONTO, July 25, 2025 /CNW/ – CIBC announced today it has been recognized as a Best Place to Work for Disability Inclusion after earning a top score on the 2025 Canada Disability Index®. This recognition underscores CIBC's ongoing commitment to matching talent to opportunity and promoting a workplace where all team members can flourish. The Disability Index® is a leading third-party benchmarking tool for workplace disability inclusion, and measures performance across key areas such as culture and leadership, enterprise-wide access, employment practices, community engagement, and supplier inclusion. 'At CIBC, inclusion is the cornerstone of our bank's culture. Building a workforce that reflects the clients and communities we serve allows for unique perspectives, experiences, and drives innovation,' said Sandy Sharman, Group Head, People, Culture and Brand, CIBC. 'This recognition reinforces our commitment to supporting our team members and empowering them to achieve their ambitions.' By achieving this distinction, CIBC joins hundreds of global organizations dedicated to advancing accessibility and supporting 1.3 billion people with disabilities worldwide1. To learn more about our commitments, visit Accessibility at CIBC. About CIBC CIBC is a leading North American financial institution with 14 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world. Ongoing news releases and more information about CIBC can be found at _____________________1 World Health Organization. 'Disability and Health.' WHO, 13 March 2023.
Malaysian Reserve
24-07-2025
- Malaysian Reserve
Blenrep (belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma
Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed1,2,3 First and only approved anti-BCMA-ADC for the treatment of multiple myeloma in Canada MISSISSAUGA, ON, July 23, 2025 /CNW/ – GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with bortezomib and dexamethasone, or in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide for the latter combination. Superior efficacy results, when compared to standard of care, from the pivotal DREAMM-7 and DREAMM-8 phase III trials in relapsed or refractory multiple myeloma support the approval of the Blenrep combinations. These include statistically significant and clinically meaningful progression-free survival (PFS) results versus standards of care in both trials and overall survival (OS) in DREAMM-7.2,3,4 The safety and tolerability profiles of the Blenrep combinations were broadly consistent with the known profiles of the individual agents.2,3 'The approval of Blenrep in Canada represents an advancement for patients with multiple myeloma, a challenging condition marked by repeated cycles of remission and relapse,' said Michelle Horn, Country Medical Head, GSK Canada. 'As the only BCMA-targeted antibody-drug conjugate, Blenrep has been shown to extend survival and remission, supported by data from the DREAMM-7 and DREAMM-8 phase III clinical trials. This approval marks a milestone in offering a treatment option that holds the promise to transform the therapeutic approach for patients facing their first or subsequent relapses.' Blenrep is the first and only anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (ADC) for multiple myeloma, providing patients facing their first and subsequent relapses with a differentiated mechanism of action. Blenrep combinations can be administered to a broad range of patient types without complex pre-administration regimens or hospitalization. 'As patients with multiple myeloma receive combination therapies at diagnosis, the availability of diverse treatment options like Blenrep is vital for prolonging remission and enhancing survival outcomes,' said Martine Elias, Chief Executive Officer of Myeloma Canada. 'This milestone represents a transformative step forward in the treatment landscape, empowering our community and reinforcing our commitment to making myeloma matter while driving progress toward a cure.' In the DREAMM-7 and DREAMM-8 clinical trials, Blenrep combinations consistently benefited a broad range of patients, including those with poor prognostic features or outcomes, such as high-risk cytogenetics or those refractory to lenalidomide. Both trials also showed clinically meaningful improvements across all secondary efficacy endpoints, including deeper and more durable responses versus the respective comparators.2,3 The most common adverse reactions, occurring in ≥20% of patients, were reduced visual acuity (BCVA), corneal examination findings, blurred vision, dry eye, photophobia, foreign body sensation in eyes, eye irritation, eye pain, cataract, upper respiratory tract infection, pneumonia, fatigue, thrombocytopenia, diarrhea, and peripheral sensory neuropathy. Eye-related side effects, a known side effect of treatment with Blenrep, were manageable with extended time between infusions and dose reductions, while maintaining efficacy, and led to low (≤9%) treatment discontinuations in both trials.2,3 About multiple myelomaMultiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable.5,6 There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year.7 Multiple myeloma is a significant concern in Canada, where in 2024 alone, 4,000 people were diagnosed with the disease.8 Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments.1 About Blenrep Blenrep is an ADC comprising a humanized BCMA monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker. In Canada, Blenrep (belantamab mafodotin for injection) is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. Specifically, Blenrep is indicated: in combination with bortezomib and dexamethasone (BVd), in adult patients who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone (BPd), in adult patients who have received at least one prior line of therapy, including lenalidomide. Please consult the Product Monograph at for complete safety information. The Product Monograph is also available by calling 1-800-387-7374. About DREAMM-7DREAMM-7 is a multicentre, open-label, randomized phase III clinical trial evaluating the efficacy and safety of belantamab mafodotin combined with bortezomib plus dexamethasone (BVd) compared to daratumumab combined with bortezomib plus dexamethasone (DVd) in adult patients with relapsed or refractory multiple myeloma who previously were treated with at least one prior line of multiple myeloma therapy. The trial enrolled 494 participants who were randomized 1:1 to receive either BVd or DVd for eight cycles, after which patients received belantamab mafodotin or daratumumab as a monotherapy. The primary endpoint was PFS as per an independent review committee, with secondary endpoints including OS, duration of response (DOR), and minimal residual disease (MRD) negativity. Other secondary endpoints include overall response rate (ORR), safety, and patient-reported quality-of-life outcomes. The Blenrep combination demonstrated a statistically significant and clinically meaningful improvement in PFS. The median PFS was 36.6 months (95% CI: 28.4-not reached [NR]) with BVd compared to 13.4 months (11.1-17.5) with DVd (hazard ratio for disease progression or death, 0.41; 95% CI, 0.31 to 0.53; P<0.001). For Overall Survival (OS), at the first pre-planned interim analysis, the hazard ratio was 0.57; 95% CI, 0.40, 0.80, indicating a 43% reduction in the risk of death in favour of BVd. More recently, the updated OS results were statistically significant and maintained the reduction in the risk of death in favour of BVd. These results were presented at the American Society of Hematology (ASH) Annual Meeting in December 2024.2,4 These findings were consistently observed in subgroups and supported by secondary endpoints. About DREAMM-8DREAMM-8 is a multicentre, open-label, randomized phase III clinical trial evaluating the efficacy and safety of belantamab mafodotin in combination with pomalidomide plus dexamethasone (BPd) compared to bortezomib and pomalidomide plus dexamethasone (PVd) in adult patients with relapsed/refractory multiple myeloma previously treated with at least one prior line of multiple myeloma therapy, including a lenalidomide-containing regimen. The trial included 302 participants who were randomized 1:1 to receive either BPd or PVd. Patients in DREAMM-8 were more heavily pre-treated in that all had prior exposure to lenalidomide, 81% were refractory to lenalidomide, 25% had prior anti-CD38 exposure and of those most were daratumumab refractory. Belantamab mafodotin was administered at a dose of 2.5mg/kg intravenously for the first cycle and then 1.9mg/kg intravenously every four weeks. The primary endpoint was PFS as per an independent review committee, with key secondary endpoints including OS and MRD negativity rate as assessed by next-generation sequencing. Other secondary endpoints include ORR, DOR, safety, and patient-reported quality-of-life outcomes. In DREAMM-8, the Blenrep combination demonstrated a statistically significant and clinically meaningful improvement in PFS, with a 48% reduction in the risk of disease progression or death compared to PVd (HR: 0.52 [95% CI: 0.37-0.73], p-value<0.001). At the primary analysis, with a median follow-up of 21.8 months, the median PFS was not yet reached (95% CI: 20.6-not yet reached [NR]) with BPd compared to 12.7 months (95% CI: 9.1-18.5) for PVd. Recently, in an updated interim analysis, after a median follow-up of 28.01 months, the mPFS in the BPd arm was 32.6 months compared with 12.5 months in the PVd arm. These results were presented at the European Hematology Association (EHA) Annual Meeting in June 2025.9 The clinical benefit for BPd was observed across all pre-specified subgroups including those with poor prognostic features, such as patients who were refractory to lenalidomide and patients with high-risk cytogenetics. GSK in OncologyOur ambition in oncology is to help increase overall quality of life, maximise survival, and change the course of disease, expanding from our current focus on blood and women's cancers into lung and gastrointestinal cancers, as well as other solid tumours. This includes accelerating priority programmes such as antibody-drug conjugates targeting B7-H3 and B7-H4, and IDRX-42, a highly selective KIT tyrosine kinase inhibitor. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the 'Risk Factors' section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. References _______________________ 1 Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015;125(20). doi:10.1182/blood-2014-11-568923. 2 Hungria V, Robak P, Hus M et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. PMID: 38828933. 3 Dimopoulos MA, Beksac M, Pour L, Delimpasi S et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2. PMID: 38828951. 4 Hungria V, Robak P, H Marek et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial. Presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. December 2024 5 Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660. 6 Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676– 10.1053/ 7 Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Multiple Myeloma fact sheet. Available at: Accessed 5 March 2025. 8 Multiple myeloma statistics. Canadian Cancer Society. Available at: Accessed 11 July 2025. 9 UPDATED RESULTS FROM PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN… – Dimopoulos M – EHA-3268 – Jun 13 2025, Available at:
